Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PBMD only dipped to 5.22 now headed to take out 6.00 again. Man this thing is STRONG!
May dip to $5.00 here. I saw a trade at $5 go through for 300K shares. Somebody thought that was a pretty good entry. LOL I may have to hit it again depending upon how it looks when it gets there, if it gets there,and I think it will.
Yah, that 6.48 may be the top today. I exited at 6.34. THANKS FOR THE HEADS UP!
PBMD...$7 doesn't look out of the question.
PBMD hit $5.95. $6.00 break coming!
PBMD 4.99 up 210%. AWESOME!!!
PBMD 4.88 UP 205%
PBMD goin insane! 3.87 up 141%
TCON 12.20 UP 12.3%: They received a fast track designation for RCC. Stock had been under pressure lately and took a hit. Went down to $10. Today its back to mid 12's and we should be expecting data release end of may early June. The current price target on this is set by 6 analysts at $26. Worth a radar.
TRACON's TRC105 Receives FDA Fast Track Designation
TRACON Pharmaceuticals, Inc.
23 hours ago
GlobeNewswire
????
SAN DIEGO, May 14, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of TRC105 in patients with advanced renal cell carcinoma (RCC) that have progressed following treatment with one inhibitor of the VEGF pathway in combination with standard dose Inlyta(R) (axitinib).
"We are pleased to receive fast track designation for TRC105 for the treatment of patients with advanced renal cell carcinoma," said Charles P. Theuer, MD, PhD, President and CEO of TRACON. "Angiogenesis drives tumor growth in renal cell carcinoma and despite multiple products approved to treat the disease, resistance to treatments remains a serious challenge. We remain encouraged by data presented at GU ASCO indicating the combination of TRC105 with Inlyta was well tolerated and demonstrated signs of activity in patients who progressed on prior VEGF inhibitors, including Sutent(R) (sunitinib) and Votrient(R) (pazopanib), as well as immune checkpoint inhibitor treatment."
The FDA created the Fast Track designation process to facilitate the development and expedite the review of drugs to treat serious diseases and address unmet medical needs. Fast Track designation confers important benefits, including the potential eligibility for Priority Review of a New Drug Application, if relevant criteria are met.
TRACON is sponsoring a multicenter, open-label, randomized clinical trial of TRC105 in combination with AXitinib in patients with Advanced or metastatic RCC (TRAXAR). The primary endpoint of the Phase 2b study is progression-free survival. Approximately 150 patients with clear cell RCC who have failed one prior VEGF inhibitor are expected to enroll in the study. Patients may have also failed one prior mTOR inhibitor and one prior immunotherapy. For additional information on this clinical trial, please visit www.clinicaltrials.gov, identifier NCT01806064.
About Advanced Renal Cell Carcinoma
The American Cancer Society's 2015 statistics cite kidney cancer as among the top ten most commonly diagnosed forms of cancer among both men and women in the United States.1 Clear cell RCC is the most common type of kidney cancer in adults.2 If detected in its early stages, the five-year survival rate for RCC is high; however, the five-year survival rate for patients with advanced or late-stage metastatic RCC is under 10 percent, with no identified cure for the disease.3
Related Quotes
4:06 pm Tracon Pharmaceuticals announces that TRC105 has received FDA fast track designation Briefing.com 23 hrs ago
More
About TRC105
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in clinical trials sponsored by both TRACON and the National Cancer Institute for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC105 is also being developed in combination with VEGF inhibitor treatments in age-related macular degeneration. For more information about the clinical trials, please visit TRACON's website at http://www.traconpharma.com/clinical_trials.php.
About TRACON
TRACON develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
1 Cancer Facts & Figures 2015. American Cancer Society. Available at http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf
2 American Cancer Society, 2014. Available at http://www.cancer.org/acs/groups/cid/documents/webcontent/003107-pdf.pdf
3 http://www.cancer.org/cancer/kidneycancer/detailedguide/kidney-cancer-adult-survival-rates
Contact:
Casey Logan
Chief Business Officer
(858) 550-0780 ext. 236
clogan@traconpharma.com
*******************************************************************
TRACON Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting
TRACON Pharmaceuticals, Inc.
May 13, 2015 5:30 PM
GlobeNewswire
????
SAN DIEGO, May 13, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, today announced presentations for both TRC105 and TRC102 at the upcoming American Society of Clinical Oncology (ASCO) annual meeting to be held May 29-June 2, 2015, in Chicago, Illinois.
The following is a summary of the four presentations that will be given at ASCO:
Poster Discussion Presentation
Title: A Phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with
pazopanib in patients with advanced soft tissue sarcoma (Abstract #10514)
Presenter: Steven Attia, DO, Mayo Clinic-Jacksonville
Location: S Hall A, Poster Board 158 (poster display)
S404 (poster discussion)
Date/Time: Sunday, May 31, 2015, 8:00 AM -- 11:30 AM, Central time (poster display)
Sunday, May 31, 2015, 4:30 PM -- 5:45 PM, Central time (poster discussion)
General Poster Presentations
Title: Phase 1 clinical trial of temozolomide and methoxyamine (TRC102) in patients with
advanced solid tumors (Abstract #2558)
Presenter: Jennifer Rachel Eads, MD, Case Comprehensive Cancer Center, Case Western Reserve University
Location: S Hall A, Poster Board 274
Date/Time: Saturday, May 30, 2015, 8:00 AM -- 11:30 AM, Central time
Title: A Phase 1/2 study of TRC105 in combination with sorafenib in hepatocellular
carcinoma (Abstract #4083)
Presenter: Austin G. Duffy, MD, National Cancer Institute
Location: S Hall A, Poster Board 193
Date/Time: Monday, June 1, 2015, 8:00 AM -- 11:30 AM, Central time
Title: Bevacizumab alone or in combination with TRC105 for metastatic renal cell cancer
(mRCC): A California Cancer Consortium clinical trial (Abstract #4542)
Presenter: Tanya Dorff, MD, University of Southern California Norris Comprehensive Cancer Center
Location: S Hall A, Poster Board 215
Date/Time: Monday, June 1, 2015, 1:15 PM -- 4:45 PM, Central time
About TRC105
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in clinical trials sponsored by both TRACON and the National Cancer Institute for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC105 is also being developed in combination with VEGF inhibitor treatments in age-related macular degeneration. For more information about the clinical trials, please visit TRACON's website at http://www.traconpharma.com/clinical_trials.php.
About TRC102
TRC102 is a novel, clinical stage small molecule inhibitor of the DNA base excision repair pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is currently being studied in clinical trials sponsored by both the National Cancer Institute and Case Comprehensive Cancer Center. For more information about the clinical trials, please visit TRACON's website at http://www.traconpharma.com/clinical_trials.php.
About TRACON
TRACON develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Contact:
Casey Logan
Chief Business Officer
(858) 550-0780 ext. 236
clogan@traconpharma.com
BIAD .17 up 9.68%. What a difference one little trade makes. LOL
Thanks! Probably not until Fall is my guess.
UNGS current share structure:
Part B Share Structure
Item 4: The exact title and class of securities outstanding
The Company has one class of capital stock consisting of 9,000,000,000 authorized shares of Common Stock of which 4,910,250,000 are issued and outstanding as of March 31, 2015. The Company’s trading symbol and CUSIP number are UNGS and 871324 109 (formerly 90345C 207), respectively.
On November 24, 2014, the Company filed an Amendment to its Articles of Incorporation increasing the Authorized number of common shares from 5,000,000,000 to 9,000,000,000. No changes were made to the Company's Preferred share structure.
On August 21, 2014, the Company filed an Amendment to its Articles of Incorporation increasing the Authorized number of common shares from 2,000,000,000 to 5,000,000,000. No changes were made to the Company's Preferred share structure.
On August 12, 2013, the Company effectively completed a 1:300 reverse stock split of its common stock.
On July 19, 2013, the Company filed an Amendment to its articles of Incorporation reducing the Authorized number of common shares from 9,000,000,000 to 2,000,000,000 and to effectively reduce the number of common shares outstanding through a 1:300 reverse stock split.
http://www.otcmarkets.com/financialReportViewer?symbol=UNGS&id=138058
Well, I guess I found the right abstract after all. LOL
JJ
EXCELLENT read! Clearly Kaplan is ready to beotch slap ZTE down if they do not fully comply with his Order, and that also includes their legal counsel. It's not often the judge points his mighty finger at legal counsel, but those folks have also been warned in no uncertain terms.
BIAD..no surprises in that Q. Expenses down, but they paid that 300K shares to the IR. Otherwise I didn't see any surprises. NOW we just need that news to come EOM.
Wonder if TPIV will release a PR on the abstract today?
Do they have more than one abstract with the same identical name??????
I got the name of it from jbem's post. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113527205
That's the same name on that abstract. I guess there's more than one with the same name. My apologies! I wouldn't have thought that.
JJ
TPIV---HERE'S THE ABSTRACT: http://abstracts.asco.org/156/AbstView_156_148110.html
A phase I trial of the safety and immunogenicity of a multi-epitope folate receptor alpha peptide vaccine used in combination with cyclophosphamide in subjects previously treated for breast or ovarian cancer.
Sub-category:
Vaccines
Category:
Developmental Therapeutics—Immunotherapy
Meeting:
2015 ASCO Annual Meeting
Abstract No:
e14028
Citation:
J Clin Oncol 33:5s, 2015 (suppl; abstr e14028)
Author(s): Pashtoon Murtaza Kasi, Kimberly Kalli, Matthew Stephen Block, Timothy J. Hobday, Travis J. Dockter, Vera J. Suman, Courtney L. Erskine, Daniel W. Visscher, Glynn Wilson, Barath Shreeder, Keith L. Knutson; Mayo School of Graduate Medcl Education, Rochester, MN; Mayo Clinic, Rochester, MN; Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN; TapImmune, Seattle, WA; Cancer Vaccines and Immune Therapies Program, Center for Diseases of Aging, Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL; Vaccine and Gene Thrpy Inst of Florida, Port St Lucie, FL
Abstract Disclosures
Abstract:
Background: Folate receptor alpha (FRa) is overexpressed by multiple cancers, including breast and ovarian cancers. Endogenous T-cell immunity to each of five degenerate peptides from FRa (FR30, FR56, FR76, FR113 and FR238) has been demonstrated in both breast and ovarian cancer patients, suggesting the feasibility of targeting FRa via a vaccine approach. Metronomic oral cyclophosphamide (CTX) has been demonstrated to reduce immunosuppressive T regulatory cells (Tregs) and might thereby improve vaccine efficacy. We therefore conducted a Phase I clinical trial testing safety and immunogenicity of a multi-epitope FRa peptide vaccine after 1 cycle of CTX. Methods: Twenty-two patients with breast or ovarian cancer who had undergone standard surgery and adjuvant treatment were treated with 1 cycle of CTX (given days 1-7 and 15-22 of 28). Following this, patients were vaccinated intradermally at 3 sites with a mixture of the 5 FRa peptides on day 1 of a 28 day cycle for a maximum of 6 vaccination cycles. Patients were monitored for toxicity at each visit. Peripheral blood samples were collected for immune monitoring purposes at baseline, at the completion of each cycle of treatment, and at during observation at 3, 6, and 12 months after vaccine completion. The number of Tregs was assessed via flow cytometry, and the number of antigen-specific T cells was assessed via ELIspot. Results: Of 22 patients evaluable for toxicity, one patient developed a grade 3 injection site reaction. Grade 2 reactions were observed in 14 patients and included lymphopenia (5), neutropenia (4), injection site reactions (2), and leukopenia (2). The median frequency of Tregs did not significantly change after CTX use. However, FRa-specific T cell responses were observed in 20 of 21 patients with immune response data. Of these, 16 of 16 patients with observation data had demonstrable T cell responses persisting into the observation phase. Conclusions: Vaccine treatments were associated with mild to moderate toxicity. FRa specific T cell responses were induced in the majority of patients and frequently persisted after completion of vaccine therapy. Clinical trial information: NCT01606241
TPIV-HERE'S THE ABSTRACT: http://abstracts.asco.org/156/AbstView_156_148110.html
A phase I trial of the safety and immunogenicity of a multi-epitope folate receptor alpha peptide vaccine used in combination with cyclophosphamide in subjects previously treated for breast or ovarian cancer.
Sub-category:
Vaccines
Category:
Developmental Therapeutics—Immunotherapy
Meeting:
2015 ASCO Annual Meeting
Abstract No:
e14028
Citation:
J Clin Oncol 33:5s, 2015 (suppl; abstr e14028)
Author(s): Pashtoon Murtaza Kasi, Kimberly Kalli, Matthew Stephen Block, Timothy J. Hobday, Travis J. Dockter, Vera J. Suman, Courtney L. Erskine, Daniel W. Visscher, Glynn Wilson, Barath Shreeder, Keith L. Knutson; Mayo School of Graduate Medcl Education, Rochester, MN; Mayo Clinic, Rochester, MN; Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN; TapImmune, Seattle, WA; Cancer Vaccines and Immune Therapies Program, Center for Diseases of Aging, Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL; Vaccine and Gene Thrpy Inst of Florida, Port St Lucie, FL
Abstract Disclosures
Abstract:
Background: Folate receptor alpha (FRa) is overexpressed by multiple cancers, including breast and ovarian cancers. Endogenous T-cell immunity to each of five degenerate peptides from FRa (FR30, FR56, FR76, FR113 and FR238) has been demonstrated in both breast and ovarian cancer patients, suggesting the feasibility of targeting FRa via a vaccine approach. Metronomic oral cyclophosphamide (CTX) has been demonstrated to reduce immunosuppressive T regulatory cells (Tregs) and might thereby improve vaccine efficacy. We therefore conducted a Phase I clinical trial testing safety and immunogenicity of a multi-epitope FRa peptide vaccine after 1 cycle of CTX. Methods: Twenty-two patients with breast or ovarian cancer who had undergone standard surgery and adjuvant treatment were treated with 1 cycle of CTX (given days 1-7 and 15-22 of 28). Following this, patients were vaccinated intradermally at 3 sites with a mixture of the 5 FRa peptides on day 1 of a 28 day cycle for a maximum of 6 vaccination cycles. Patients were monitored for toxicity at each visit. Peripheral blood samples were collected for immune monitoring purposes at baseline, at the completion of each cycle of treatment, and at during observation at 3, 6, and 12 months after vaccine completion. The number of Tregs was assessed via flow cytometry, and the number of antigen-specific T cells was assessed via ELIspot. Results: Of 22 patients evaluable for toxicity, one patient developed a grade 3 injection site reaction. Grade 2 reactions were observed in 14 patients and included lymphopenia (5), neutropenia (4), injection site reactions (2), and leukopenia (2). The median frequency of Tregs did not significantly change after CTX use. However, FRa-specific T cell responses were observed in 20 of 21 patients with immune response data. Of these, 16 of 16 patients with observation data had demonstrable T cell responses persisting into the observation phase. Conclusions: Vaccine treatments were associated with mild to moderate toxicity. FRa specific T cell responses were induced in the majority of patients and frequently persisted after completion of vaccine therapy. Clinical trial information: NCT01606241
TY! I added the text to my post.
HERE'S THE ABSTRACT: http://abstracts.asco.org/156/AbstView_156_148110.html
A phase I trial of the safety and immunogenicity of a multi-epitope folate receptor alpha peptide vaccine used in combination with cyclophosphamide in subjects previously treated for breast or ovarian cancer.
Sub-category:
Vaccines
Category:
Developmental Therapeutics—Immunotherapy
Meeting:
2015 ASCO Annual Meeting
Abstract No:
e14028
Citation:
J Clin Oncol 33:5s, 2015 (suppl; abstr e14028)
Author(s): Pashtoon Murtaza Kasi, Kimberly Kalli, Matthew Stephen Block, Timothy J. Hobday, Travis J. Dockter, Vera J. Suman, Courtney L. Erskine, Daniel W. Visscher, Glynn Wilson, Barath Shreeder, Keith L. Knutson; Mayo School of Graduate Medcl Education, Rochester, MN; Mayo Clinic, Rochester, MN; Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN; TapImmune, Seattle, WA; Cancer Vaccines and Immune Therapies Program, Center for Diseases of Aging, Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL; Vaccine and Gene Thrpy Inst of Florida, Port St Lucie, FL
Abstract Disclosures
Abstract:
Background: Folate receptor alpha (FRa) is overexpressed by multiple cancers, including breast and ovarian cancers. Endogenous T-cell immunity to each of five degenerate peptides from FRa (FR30, FR56, FR76, FR113 and FR238) has been demonstrated in both breast and ovarian cancer patients, suggesting the feasibility of targeting FRa via a vaccine approach. Metronomic oral cyclophosphamide (CTX) has been demonstrated to reduce immunosuppressive T regulatory cells (Tregs) and might thereby improve vaccine efficacy. We therefore conducted a Phase I clinical trial testing safety and immunogenicity of a multi-epitope FRa peptide vaccine after 1 cycle of CTX. Methods: Twenty-two patients with breast or ovarian cancer who had undergone standard surgery and adjuvant treatment were treated with 1 cycle of CTX (given days 1-7 and 15-22 of 28). Following this, patients were vaccinated intradermally at 3 sites with a mixture of the 5 FRa peptides on day 1 of a 28 day cycle for a maximum of 6 vaccination cycles. Patients were monitored for toxicity at each visit. Peripheral blood samples were collected for immune monitoring purposes at baseline, at the completion of each cycle of treatment, and at during observation at 3, 6, and 12 months after vaccine completion. The number of Tregs was assessed via flow cytometry, and the number of antigen-specific T cells was assessed via ELIspot. Results: Of 22 patients evaluable for toxicity, one patient developed a grade 3 injection site reaction. Grade 2 reactions were observed in 14 patients and included lymphopenia (5), neutropenia (4), injection site reactions (2), and leukopenia (2). The median frequency of Tregs did not significantly change after CTX use. However, FRa-specific T cell responses were observed in 20 of 21 patients with immune response data. Of these, 16 of 16 patients with observation data had demonstrable T cell responses persisting into the observation phase. Conclusions: Vaccine treatments were associated with mild to moderate toxicity. FRa specific T cell responses were induced in the majority of patients and frequently persisted after completion of vaccine therapy. Clinical trial information: NCT01606241
TPIV ABSTRACT
250,000 share hit at .304
DATE/TIME/PPS/BID/ASK/SHARES
05/13/15 14:30:29 0.304 0.3001 0.304 250000
ASCO: Abstract Public Release (Embargo) Dates and Times
Note: All abstracts to be released onsite at the 2015 ASCO Annual Meeting will be designated as Late-Breaking Abstracts (LBAs), including Plenary abstracts.
May 13, 2015, 5:00 PM (EDT) - All abstracts part of 2015 ASCO Proceedings I will be publicly released at abstracts.asco.org.
May 13, 2015, 5:00 PM (EDT) - All Publication-Only abstracts from the 2015 ASCO Annual Meeting will be publicly released on abstracts.asco.org.
May 29, 2015, 1:00 PM (CDT) - All LBAs to be presented in a press briefing or scientific presentation on Friday, May 29 will be publicly released at 1:00 PM (CDT) on Friday, May 29, 2015, on abstracts.asco.org.
May 30, 2015, 6:30 AM (CDT) - All LBAs to be presented in a press briefing or scientific presentation on Saturday, May 30 will be publicly released at 6:30 AM (CDT) on Saturday, May 30, 2015, on abstracts.asco.org.
May 31, 2015, 6:30 AM (CDT) - All LBAs to be presented in a press briefing or scientific presentation on Sunday, May 31 will be publicly released at 6:30 AM (CDT) on Sunday, May 31, 2015, at abstracts.asco.org.
June 1, 2015, 6:30 AM (CDT) - All LBAs to be presented in a press briefing or scientific presentation on Monday, June 1 and Tuesday, June 2 will be publicly released at 6:30 AM (CDT) on Monday, June 1, 2015, at abstracts.asco.org.
http://am.asco.org/embargo-and-release-information
Good to see you as well, lasers. Best of luck!!!
JJ
Nice day of consolidation! Higher high, higher low, and closed green.
TPIV already 4.1M volume today. Gonna break yesterdays volume.
ASCO Embargo and Release Information
Abstract Public Release (Embargo) Dates and Times
Note: All abstracts to be released onsite at the 2015 ASCO Annual Meeting will be designated as Late-Breaking Abstracts (LBAs), including Plenary abstracts.
May 13, 2015, 5:00 PM (EDT) - All abstracts part of 2015 ASCO Proceedings I will be publicly released at abstracts.asco.org.
May 13, 2015, 5:00 PM (EDT) - All Publication-Only abstracts from the 2015 ASCO Annual Meeting will be publicly released on abstracts.asco.org.
May 29, 2015, 1:00 PM (CDT) - All LBAs to be presented in a press briefing or scientific presentation on Friday, May 29 will be publicly released at 1:00 PM (CDT) on Friday, May 29, 2015, on abstracts.asco.org.
May 30, 2015, 6:30 AM (CDT) - All LBAs to be presented in a press briefing or scientific presentation on Saturday, May 30 will be publicly released at 6:30 AM (CDT) on Saturday, May 30, 2015, on abstracts.asco.org.
May 31, 2015, 6:30 AM (CDT) - All LBAs to be presented in a press briefing or scientific presentation on Sunday, May 31 will be publicly released at 6:30 AM (CDT) on Sunday, May 31, 2015, at abstracts.asco.org.
June 1, 2015, 6:30 AM (CDT) - All LBAs to be presented in a press briefing or scientific presentation on Monday, June 1 and Tuesday, June 2 will be publicly released at 6:30 AM (CDT) on Monday, June 1, 2015, at abstracts.asco.org.
http://am.asco.org/embargo-and-release-information
ASCO Embargo and Release Information
Abstract Public Release (Embargo) Dates and Times
Note: All abstracts to be released onsite at the 2015 ASCO Annual Meeting will be designated as Late-Breaking Abstracts (LBAs), including Plenary abstracts.
May 13, 2015, 5:00 PM (EDT) - All abstracts part of 2015 ASCO Proceedings I will be publicly released at abstracts.asco.org.
May 13, 2015, 5:00 PM (EDT) - All Publication-Only abstracts from the 2015 ASCO Annual Meeting will be publicly released on abstracts.asco.org.
May 29, 2015, 1:00 PM (CDT) - All LBAs to be presented in a press briefing or scientific presentation on Friday, May 29 will be publicly released at 1:00 PM (CDT) on Friday, May 29, 2015, on abstracts.asco.org.
May 30, 2015, 6:30 AM (CDT) - All LBAs to be presented in a press briefing or scientific presentation on Saturday, May 30 will be publicly released at 6:30 AM (CDT) on Saturday, May 30, 2015, on abstracts.asco.org.
May 31, 2015, 6:30 AM (CDT) - All LBAs to be presented in a press briefing or scientific presentation on Sunday, May 31 will be publicly released at 6:30 AM (CDT) on Sunday, May 31, 2015, at abstracts.asco.org.
June 1, 2015, 6:30 AM (CDT) - All LBAs to be presented in a press briefing or scientific presentation on Monday, June 1 and Tuesday, June 2 will be publicly released at 6:30 AM (CDT) on Monday, June 1, 2015, at abstracts.asco.org.
http://am.asco.org/embargo-and-release-information
TPIV...NHOD may be about to strike.
Nice! TPIV about 5X normal volume already this morning
MECK...ZERO volume. How do you make 150%? Buy some and let me watch you! LOL
ash111 Member Level Friday, 05/08/15 12:59:52 PM
Re: aquaspin post# 344861
Post # of 344862
MECK. could make 150% on one day trading.IMO actual float less than 3m (6m os) and CEO buying nonstop and owns now 44% of is.
PTBI-- I see support on the chart from back in November/December at 7.00. How strong that'll be I don't know.
You're welcome!
OREX Price Movement History-Earnings Announcement
http://tradingthedate.com/trading-tools/earnings-trader/dates/all?symbol=OREX
PTBI (9.65) Announces $10 Million Private Placement
1:32 pm ET May 6, 2015 (Market Wire) Print
PlasmaTech Biopharmaceuticals, Inc. ("PlasmaTech" or the "Company"), (NASDAQ: PTBI), announced today that it has entered into a definitive agreement with one institutional investor in a private placement of approximately $10 million of common stock at a price of $8.00 per share, or 1,250,000 shares.
In addition, the Company will issue to the investors warrants to purchase 625,000 shares of common stock. The warrants have an exercise price of $10.00 per share and are exercisable for 30 months from the closing date.
The offering is expected to close on or about May 11, 2015, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co. acted as the exclusive placement agent for the transaction.
The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investors, the Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock and shares issuable upon exercise of the warrants within 30 days of the closing date.
This release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.
EXTR...I don't see where Soros is in that one, or at least nothing recent. OCLR moving on a 2/23 12M share position he took.
PTBI---KILLER!! GREAT CALL JBEM!!!
Altucher has a lot of followers, but that dude has made some WILD predictions. In VRNG vs GOOG he predicted GOOG may be going to ZERO, and gave VRNG a $26 PT. Neither came close to happening, but the stock did get a bounce on his pick.
BIAD--posted by 3DPrintInvestor Member Level Friday, 05/01/15 12:05:35 PM
Re: None
Post # of 950
Interesting change to web site made.
They updated the web site a bit today. I think it may be due to information from the upcoming MIDS report (now due out by end of this month) that they wanted to include on the site.
Note on the MIDS page the following paragraph has been added.
"Because of its accuracy and sensitivity, MIDS, as applied to cardiac marker detection, may well be able to predict the likelihood of re-infarction post initial early symptoms, or infarction in otherwise asymptomatic patients in high risk groups. Prediction of infarction risk, stratification of that risk and definitive diagnosis is a major issue for hospitals, as they need to prioritise treatment and manage the costs of treating heart attack patients."
So their MIDS technology when used for cardiac markers may be utilized as an early indicator or even risk predictor of coronary artery disease/heart attacks in people with no symptoms or prior history.
Yes, it's still unknown if they'll ultimately commercialize this- and it may take a partnership with a larger player to make it happen, but if they do, it's an obvious gigantic market for this kind of testing that can be done in a physician's office, in hospitals, etc.
BIAD .1754...highest it's hit since April 22nd. Now if we could just get that report and some volume.